Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v16-EN Version v6-EN
Language English English
Date Updated 2023-09-01 2023-03-30
Drug Identification Number 02506270 02506270
Brand name APO-SITAGLIPTIN/METFORMIN XR APO-SITAGLIPTIN/METFORMIN XR
Common or Proper name SITAGLIPTAN PHOSPHATE/METFORMIN SITAGLIPTAN PHOSPHATE/METFORMIN
Company Name APOTEX INC APOTEX INC
Ingredients METFORMIN HYDROCHLORIDE SITAGLIPTIN METFORMIN HYDROCHLORIDE SITAGLIPTIN
Strength(s) 500MG 50MG 500MG 50MG
Dosage form(s) TABLET (EXTENDED-RELEASE) TABLET (EXTENDED-RELEASE)
Route of administration ORAL ORAL
Packaging size 60 BTL 60 BTL
ATC code A10BD A10BD
ATC description BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2023-03-02 2023-03-02
Estimated end date 2023-09-30 2023-04-28
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Product on allocation due to increased demand Product on allocation due to increased demand
Health Canada comments